Arabian Journal of Chemistry-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2147288, encodeId=58a7214e28838, content=审稿速度:3.0 经验分享：研究型论文 Initial Date Submitted 3.16 Under Review 3.18 revise and resubmit your manuscrip 6.26 返稿 7.6 Received at Editorial Office 7.7 总体感觉还是比较nice的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/1cb160e8258640c2b57d7628095e3585/e81c07fcc6594229a97371ee25978df2.jpg, createdBy=66fe2398250, createdName=tsunamis, createdTime=Mon Jul 10 13:49:29 CST 2023, time=2023-07-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2089818, encodeId=5b3b208981827, content=2022.9.14 投稿，一周多了还是with editor正常吗，可以催稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=53f15071890, createdName=1459625am12暂无昵称, createdTime=Thu Sep 22 19:44:12 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181460, encodeId=2c492181460f1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：老天保佑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbfb9144040, createdName=ms4000000349532607, createdTime=Sat Jan 13 21:00:26 CST 2024, time=2024-01-13, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2174434, encodeId=5c1221e443401, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：药效物质基础;中药学 经验分享：2023年5月28日投稿，7月30日催稿后才进入了under review,一直到10月20日催稿，被告知一直未能成功邀请审稿人，继续催稿，又一个月左右邀请了7个审稿人，6个退修，剩余1个审稿人意见比较负面，2023年12月11日被退稿，说不能录用。太扯淡了，编辑及其不负责任，一直不重新邀请审稿人，投稿半年被拒了，简直是浪费时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13718827213, createdName=ms4000000272566761, createdTime=Tue Dec 12 10:43:34 CST 2023, time=2023-12-12, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2173223, encodeId=eeb321e3223a3, content=偏重的研究方向：药物分析 经验分享：10月31号提交的，一个多月了，还在with editor。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52d66486947, createdName=ms9000001055760114, createdTime=Wed Dec 06 11:44:52 CST 2023, time=2023-12-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2129005, encodeId=df4f2129005c5, content=审稿速度:2.0 经验分享：综述 Initial Date Submitted 7.25 Under Review8.27 revise and resubmit your manuscript9.14 返稿9.26 Received at Editorial Office25 Jul 2022Article revised26 Sep 2022Article accepted for publication9 Oct 2022 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddc56394096, createdName=ms7000000595986600, createdTime=Fri Apr 28 15:10:01 CST 2023, time=2023-04-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1212273, encodeId=250d12122e361, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：返修要补部分实验，数据处理花了一定时间，给编辑发邮件说明原因后延长了一个月，但是期间还是花时间认真改了，返修第二天就收到录用通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f6e5643288, createdName=ms5000001106253574, createdTime=Mon Apr 18 20:10:06 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217201, encodeId=dd0e121e201a5, content=2.3开始外审，已经三个月了😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e55679937, createdName=ms5000001105610949, createdTime=Thu May 05 22:24:49 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235320, encodeId=da4b123532044, content=已经四个月了还在under review，是希望不大了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a0e8252933, createdName=ms3000001828306819, createdTime=Thu Jul 28 18:05:11 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232397, encodeId=3fc7123239e9f, content=为何发表在Arabian Journal of Chemistry上的文章WOS检索不到？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e001326649, createdName=kezhang0601, createdTime=Thu Jul 14 11:07:55 CST 2022, time=2022-07-14, status=1, ipAttribution=)]

2023-07-10 tsunamis 来自浙江省

审稿速度:3.0
经验分享：研究型论文
Initial Date Submitted 3.16
Under Review 3.18
revise and resubmit your manuscrip 6.26
返稿 7.6
Received at Editorial Office 7.7
总体感觉还是比较nice的。

30 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2147288, encodeId=58a7214e28838, content=审稿速度:3.0 经验分享：研究型论文 Initial Date Submitted 3.16 Under Review 3.18 revise and resubmit your manuscrip 6.26 返稿 7.6 Received at Editorial Office 7.7 总体感觉还是比较nice的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/1cb160e8258640c2b57d7628095e3585/e81c07fcc6594229a97371ee25978df2.jpg, createdBy=66fe2398250, createdName=tsunamis, createdTime=Mon Jul 10 13:49:29 CST 2023, time=2023-07-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2089818, encodeId=5b3b208981827, content=2022.9.14 投稿，一周多了还是with editor正常吗，可以催稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=53f15071890, createdName=1459625am12暂无昵称, createdTime=Thu Sep 22 19:44:12 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181460, encodeId=2c492181460f1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：老天保佑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbfb9144040, createdName=ms4000000349532607, createdTime=Sat Jan 13 21:00:26 CST 2024, time=2024-01-13, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2174434, encodeId=5c1221e443401, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：药效物质基础;中药学 经验分享：2023年5月28日投稿，7月30日催稿后才进入了under review,一直到10月20日催稿，被告知一直未能成功邀请审稿人，继续催稿，又一个月左右邀请了7个审稿人，6个退修，剩余1个审稿人意见比较负面，2023年12月11日被退稿，说不能录用。太扯淡了，编辑及其不负责任，一直不重新邀请审稿人，投稿半年被拒了，简直是浪费时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13718827213, createdName=ms4000000272566761, createdTime=Tue Dec 12 10:43:34 CST 2023, time=2023-12-12, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2173223, encodeId=eeb321e3223a3, content=偏重的研究方向：药物分析 经验分享：10月31号提交的，一个多月了，还在with editor。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52d66486947, createdName=ms9000001055760114, createdTime=Wed Dec 06 11:44:52 CST 2023, time=2023-12-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2129005, encodeId=df4f2129005c5, content=审稿速度:2.0 经验分享：综述 Initial Date Submitted 7.25 Under Review8.27 revise and resubmit your manuscript9.14 返稿9.26 Received at Editorial Office25 Jul 2022Article revised26 Sep 2022Article accepted for publication9 Oct 2022 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddc56394096, createdName=ms7000000595986600, createdTime=Fri Apr 28 15:10:01 CST 2023, time=2023-04-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1212273, encodeId=250d12122e361, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：返修要补部分实验，数据处理花了一定时间，给编辑发邮件说明原因后延长了一个月，但是期间还是花时间认真改了，返修第二天就收到录用通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f6e5643288, createdName=ms5000001106253574, createdTime=Mon Apr 18 20:10:06 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217201, encodeId=dd0e121e201a5, content=2.3开始外审，已经三个月了😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e55679937, createdName=ms5000001105610949, createdTime=Thu May 05 22:24:49 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235320, encodeId=da4b123532044, content=已经四个月了还在under review，是希望不大了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a0e8252933, createdName=ms3000001828306819, createdTime=Thu Jul 28 18:05:11 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232397, encodeId=3fc7123239e9f, content=为何发表在Arabian Journal of Chemistry上的文章WOS检索不到？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e001326649, createdName=kezhang0601, createdTime=Thu Jul 14 11:07:55 CST 2022, time=2022-07-14, status=1, ipAttribution=)]

2022-09-22 1459625am12暂无昵称

2022.9.14 投稿，一周多了还是with editor正常吗，可以催稿了吗

35 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2147288, encodeId=58a7214e28838, content=审稿速度:3.0 经验分享：研究型论文 Initial Date Submitted 3.16 Under Review 3.18 revise and resubmit your manuscrip 6.26 返稿 7.6 Received at Editorial Office 7.7 总体感觉还是比较nice的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/1cb160e8258640c2b57d7628095e3585/e81c07fcc6594229a97371ee25978df2.jpg, createdBy=66fe2398250, createdName=tsunamis, createdTime=Mon Jul 10 13:49:29 CST 2023, time=2023-07-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2089818, encodeId=5b3b208981827, content=2022.9.14 投稿，一周多了还是with editor正常吗，可以催稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=53f15071890, createdName=1459625am12暂无昵称, createdTime=Thu Sep 22 19:44:12 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181460, encodeId=2c492181460f1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：老天保佑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbfb9144040, createdName=ms4000000349532607, createdTime=Sat Jan 13 21:00:26 CST 2024, time=2024-01-13, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2174434, encodeId=5c1221e443401, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：药效物质基础;中药学 经验分享：2023年5月28日投稿，7月30日催稿后才进入了under review,一直到10月20日催稿，被告知一直未能成功邀请审稿人，继续催稿，又一个月左右邀请了7个审稿人，6个退修，剩余1个审稿人意见比较负面，2023年12月11日被退稿，说不能录用。太扯淡了，编辑及其不负责任，一直不重新邀请审稿人，投稿半年被拒了，简直是浪费时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13718827213, createdName=ms4000000272566761, createdTime=Tue Dec 12 10:43:34 CST 2023, time=2023-12-12, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2173223, encodeId=eeb321e3223a3, content=偏重的研究方向：药物分析 经验分享：10月31号提交的，一个多月了，还在with editor。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52d66486947, createdName=ms9000001055760114, createdTime=Wed Dec 06 11:44:52 CST 2023, time=2023-12-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2129005, encodeId=df4f2129005c5, content=审稿速度:2.0 经验分享：综述 Initial Date Submitted 7.25 Under Review8.27 revise and resubmit your manuscript9.14 返稿9.26 Received at Editorial Office25 Jul 2022Article revised26 Sep 2022Article accepted for publication9 Oct 2022 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddc56394096, createdName=ms7000000595986600, createdTime=Fri Apr 28 15:10:01 CST 2023, time=2023-04-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1212273, encodeId=250d12122e361, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：返修要补部分实验，数据处理花了一定时间，给编辑发邮件说明原因后延长了一个月，但是期间还是花时间认真改了，返修第二天就收到录用通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f6e5643288, createdName=ms5000001106253574, createdTime=Mon Apr 18 20:10:06 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217201, encodeId=dd0e121e201a5, content=2.3开始外审，已经三个月了😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e55679937, createdName=ms5000001105610949, createdTime=Thu May 05 22:24:49 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235320, encodeId=da4b123532044, content=已经四个月了还在under review，是希望不大了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a0e8252933, createdName=ms3000001828306819, createdTime=Thu Jul 28 18:05:11 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232397, encodeId=3fc7123239e9f, content=为何发表在Arabian Journal of Chemistry上的文章WOS检索不到？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e001326649, createdName=kezhang0601, createdTime=Thu Jul 14 11:07:55 CST 2022, time=2022-07-14, status=1, ipAttribution=)]

2024-01-13 ms4000000349532607 来自河北省

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：医学
经验分享：老天保佑

20 0

[GetPortalCommentsPageByObjectIdResponse(id=2147288, encodeId=58a7214e28838, content=审稿速度:3.0 经验分享：研究型论文 Initial Date Submitted 3.16 Under Review 3.18 revise and resubmit your manuscrip 6.26 返稿 7.6 Received at Editorial Office 7.7 总体感觉还是比较nice的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/1cb160e8258640c2b57d7628095e3585/e81c07fcc6594229a97371ee25978df2.jpg, createdBy=66fe2398250, createdName=tsunamis, createdTime=Mon Jul 10 13:49:29 CST 2023, time=2023-07-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2089818, encodeId=5b3b208981827, content=2022.9.14 投稿，一周多了还是with editor正常吗，可以催稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=53f15071890, createdName=1459625am12暂无昵称, createdTime=Thu Sep 22 19:44:12 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181460, encodeId=2c492181460f1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：老天保佑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbfb9144040, createdName=ms4000000349532607, createdTime=Sat Jan 13 21:00:26 CST 2024, time=2024-01-13, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2174434, encodeId=5c1221e443401, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：药效物质基础;中药学 经验分享：2023年5月28日投稿，7月30日催稿后才进入了under review,一直到10月20日催稿，被告知一直未能成功邀请审稿人，继续催稿，又一个月左右邀请了7个审稿人，6个退修，剩余1个审稿人意见比较负面，2023年12月11日被退稿，说不能录用。太扯淡了，编辑及其不负责任，一直不重新邀请审稿人，投稿半年被拒了，简直是浪费时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13718827213, createdName=ms4000000272566761, createdTime=Tue Dec 12 10:43:34 CST 2023, time=2023-12-12, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2173223, encodeId=eeb321e3223a3, content=偏重的研究方向：药物分析 经验分享：10月31号提交的，一个多月了，还在with editor。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52d66486947, createdName=ms9000001055760114, createdTime=Wed Dec 06 11:44:52 CST 2023, time=2023-12-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2129005, encodeId=df4f2129005c5, content=审稿速度:2.0 经验分享：综述 Initial Date Submitted 7.25 Under Review8.27 revise and resubmit your manuscript9.14 返稿9.26 Received at Editorial Office25 Jul 2022Article revised26 Sep 2022Article accepted for publication9 Oct 2022 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddc56394096, createdName=ms7000000595986600, createdTime=Fri Apr 28 15:10:01 CST 2023, time=2023-04-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1212273, encodeId=250d12122e361, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：返修要补部分实验，数据处理花了一定时间，给编辑发邮件说明原因后延长了一个月，但是期间还是花时间认真改了，返修第二天就收到录用通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f6e5643288, createdName=ms5000001106253574, createdTime=Mon Apr 18 20:10:06 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217201, encodeId=dd0e121e201a5, content=2.3开始外审，已经三个月了😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e55679937, createdName=ms5000001105610949, createdTime=Thu May 05 22:24:49 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235320, encodeId=da4b123532044, content=已经四个月了还在under review，是希望不大了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a0e8252933, createdName=ms3000001828306819, createdTime=Thu Jul 28 18:05:11 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232397, encodeId=3fc7123239e9f, content=为何发表在Arabian Journal of Chemistry上的文章WOS检索不到？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e001326649, createdName=kezhang0601, createdTime=Thu Jul 14 11:07:55 CST 2022, time=2022-07-14, status=1, ipAttribution=)]

2023-12-12 ms4000000272566761 来自贵州省

审稿速度:12.0 | 投稿命中率:25.0
偏重的研究方向：药效物质基础;中药学
经验分享：2023年5月28日投稿，7月30日催稿后才进入了under review,一直到10月20日催稿，被告知一直未能成功邀请审稿人，继续催稿，又一个月左右邀请了7个审稿人，6个退修，剩余1个审稿人意见比较负面，2023年12月11日被退稿，说不能录用。太扯淡了，编辑及其不负责任，一直不重新邀请审稿人，投稿半年被拒了，简直是浪费时间。

26 0

[GetPortalCommentsPageByObjectIdResponse(id=2147288, encodeId=58a7214e28838, content=审稿速度:3.0 经验分享：研究型论文 Initial Date Submitted 3.16 Under Review 3.18 revise and resubmit your manuscrip 6.26 返稿 7.6 Received at Editorial Office 7.7 总体感觉还是比较nice的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/1cb160e8258640c2b57d7628095e3585/e81c07fcc6594229a97371ee25978df2.jpg, createdBy=66fe2398250, createdName=tsunamis, createdTime=Mon Jul 10 13:49:29 CST 2023, time=2023-07-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2089818, encodeId=5b3b208981827, content=2022.9.14 投稿，一周多了还是with editor正常吗，可以催稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=53f15071890, createdName=1459625am12暂无昵称, createdTime=Thu Sep 22 19:44:12 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181460, encodeId=2c492181460f1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：老天保佑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbfb9144040, createdName=ms4000000349532607, createdTime=Sat Jan 13 21:00:26 CST 2024, time=2024-01-13, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2174434, encodeId=5c1221e443401, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：药效物质基础;中药学 经验分享：2023年5月28日投稿，7月30日催稿后才进入了under review,一直到10月20日催稿，被告知一直未能成功邀请审稿人，继续催稿，又一个月左右邀请了7个审稿人，6个退修，剩余1个审稿人意见比较负面，2023年12月11日被退稿，说不能录用。太扯淡了，编辑及其不负责任，一直不重新邀请审稿人，投稿半年被拒了，简直是浪费时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13718827213, createdName=ms4000000272566761, createdTime=Tue Dec 12 10:43:34 CST 2023, time=2023-12-12, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2173223, encodeId=eeb321e3223a3, content=偏重的研究方向：药物分析 经验分享：10月31号提交的，一个多月了，还在with editor。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52d66486947, createdName=ms9000001055760114, createdTime=Wed Dec 06 11:44:52 CST 2023, time=2023-12-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2129005, encodeId=df4f2129005c5, content=审稿速度:2.0 经验分享：综述 Initial Date Submitted 7.25 Under Review8.27 revise and resubmit your manuscript9.14 返稿9.26 Received at Editorial Office25 Jul 2022Article revised26 Sep 2022Article accepted for publication9 Oct 2022 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddc56394096, createdName=ms7000000595986600, createdTime=Fri Apr 28 15:10:01 CST 2023, time=2023-04-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1212273, encodeId=250d12122e361, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：返修要补部分实验，数据处理花了一定时间，给编辑发邮件说明原因后延长了一个月，但是期间还是花时间认真改了，返修第二天就收到录用通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f6e5643288, createdName=ms5000001106253574, createdTime=Mon Apr 18 20:10:06 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217201, encodeId=dd0e121e201a5, content=2.3开始外审，已经三个月了😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e55679937, createdName=ms5000001105610949, createdTime=Thu May 05 22:24:49 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235320, encodeId=da4b123532044, content=已经四个月了还在under review，是希望不大了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a0e8252933, createdName=ms3000001828306819, createdTime=Thu Jul 28 18:05:11 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232397, encodeId=3fc7123239e9f, content=为何发表在Arabian Journal of Chemistry上的文章WOS检索不到？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e001326649, createdName=kezhang0601, createdTime=Thu Jul 14 11:07:55 CST 2022, time=2022-07-14, status=1, ipAttribution=)]

2023-12-06 ms9000001055760114 来自上海

偏重的研究方向：药物分析
经验分享：10月31号提交的，一个多月了，还在with editor。。。。。

34 0

[GetPortalCommentsPageByObjectIdResponse(id=2147288, encodeId=58a7214e28838, content=审稿速度:3.0 经验分享：研究型论文 Initial Date Submitted 3.16 Under Review 3.18 revise and resubmit your manuscrip 6.26 返稿 7.6 Received at Editorial Office 7.7 总体感觉还是比较nice的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/1cb160e8258640c2b57d7628095e3585/e81c07fcc6594229a97371ee25978df2.jpg, createdBy=66fe2398250, createdName=tsunamis, createdTime=Mon Jul 10 13:49:29 CST 2023, time=2023-07-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2089818, encodeId=5b3b208981827, content=2022.9.14 投稿，一周多了还是with editor正常吗，可以催稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=53f15071890, createdName=1459625am12暂无昵称, createdTime=Thu Sep 22 19:44:12 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181460, encodeId=2c492181460f1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：老天保佑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbfb9144040, createdName=ms4000000349532607, createdTime=Sat Jan 13 21:00:26 CST 2024, time=2024-01-13, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2174434, encodeId=5c1221e443401, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：药效物质基础;中药学 经验分享：2023年5月28日投稿，7月30日催稿后才进入了under review,一直到10月20日催稿，被告知一直未能成功邀请审稿人，继续催稿，又一个月左右邀请了7个审稿人，6个退修，剩余1个审稿人意见比较负面，2023年12月11日被退稿，说不能录用。太扯淡了，编辑及其不负责任，一直不重新邀请审稿人，投稿半年被拒了，简直是浪费时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13718827213, createdName=ms4000000272566761, createdTime=Tue Dec 12 10:43:34 CST 2023, time=2023-12-12, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2173223, encodeId=eeb321e3223a3, content=偏重的研究方向：药物分析 经验分享：10月31号提交的，一个多月了，还在with editor。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52d66486947, createdName=ms9000001055760114, createdTime=Wed Dec 06 11:44:52 CST 2023, time=2023-12-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2129005, encodeId=df4f2129005c5, content=审稿速度:2.0 经验分享：综述 Initial Date Submitted 7.25 Under Review8.27 revise and resubmit your manuscript9.14 返稿9.26 Received at Editorial Office25 Jul 2022Article revised26 Sep 2022Article accepted for publication9 Oct 2022 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddc56394096, createdName=ms7000000595986600, createdTime=Fri Apr 28 15:10:01 CST 2023, time=2023-04-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1212273, encodeId=250d12122e361, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：返修要补部分实验，数据处理花了一定时间，给编辑发邮件说明原因后延长了一个月，但是期间还是花时间认真改了，返修第二天就收到录用通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f6e5643288, createdName=ms5000001106253574, createdTime=Mon Apr 18 20:10:06 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217201, encodeId=dd0e121e201a5, content=2.3开始外审，已经三个月了😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e55679937, createdName=ms5000001105610949, createdTime=Thu May 05 22:24:49 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235320, encodeId=da4b123532044, content=已经四个月了还在under review，是希望不大了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a0e8252933, createdName=ms3000001828306819, createdTime=Thu Jul 28 18:05:11 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232397, encodeId=3fc7123239e9f, content=为何发表在Arabian Journal of Chemistry上的文章WOS检索不到？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e001326649, createdName=kezhang0601, createdTime=Thu Jul 14 11:07:55 CST 2022, time=2022-07-14, status=1, ipAttribution=)]

2023-04-28 ms7000000595986600 来自山东省

审稿速度:2.0
经验分享：综述 Initial Date Submitted 7.25 Under Review8.27 revise and resubmit your manuscript9.14 返稿9.26 Received at Editorial Office25 Jul 2022Article revised26 Sep 2022Article accepted for publication9 Oct 2022

33 0

[GetPortalCommentsPageByObjectIdResponse(id=2147288, encodeId=58a7214e28838, content=审稿速度:3.0 经验分享：研究型论文 Initial Date Submitted 3.16 Under Review 3.18 revise and resubmit your manuscrip 6.26 返稿 7.6 Received at Editorial Office 7.7 总体感觉还是比较nice的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/1cb160e8258640c2b57d7628095e3585/e81c07fcc6594229a97371ee25978df2.jpg, createdBy=66fe2398250, createdName=tsunamis, createdTime=Mon Jul 10 13:49:29 CST 2023, time=2023-07-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2089818, encodeId=5b3b208981827, content=2022.9.14 投稿，一周多了还是with editor正常吗，可以催稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=53f15071890, createdName=1459625am12暂无昵称, createdTime=Thu Sep 22 19:44:12 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181460, encodeId=2c492181460f1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：老天保佑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbfb9144040, createdName=ms4000000349532607, createdTime=Sat Jan 13 21:00:26 CST 2024, time=2024-01-13, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2174434, encodeId=5c1221e443401, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：药效物质基础;中药学 经验分享：2023年5月28日投稿，7月30日催稿后才进入了under review,一直到10月20日催稿，被告知一直未能成功邀请审稿人，继续催稿，又一个月左右邀请了7个审稿人，6个退修，剩余1个审稿人意见比较负面，2023年12月11日被退稿，说不能录用。太扯淡了，编辑及其不负责任，一直不重新邀请审稿人，投稿半年被拒了，简直是浪费时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13718827213, createdName=ms4000000272566761, createdTime=Tue Dec 12 10:43:34 CST 2023, time=2023-12-12, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2173223, encodeId=eeb321e3223a3, content=偏重的研究方向：药物分析 经验分享：10月31号提交的，一个多月了，还在with editor。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52d66486947, createdName=ms9000001055760114, createdTime=Wed Dec 06 11:44:52 CST 2023, time=2023-12-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2129005, encodeId=df4f2129005c5, content=审稿速度:2.0 经验分享：综述 Initial Date Submitted 7.25 Under Review8.27 revise and resubmit your manuscript9.14 返稿9.26 Received at Editorial Office25 Jul 2022Article revised26 Sep 2022Article accepted for publication9 Oct 2022 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddc56394096, createdName=ms7000000595986600, createdTime=Fri Apr 28 15:10:01 CST 2023, time=2023-04-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1212273, encodeId=250d12122e361, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：返修要补部分实验，数据处理花了一定时间，给编辑发邮件说明原因后延长了一个月，但是期间还是花时间认真改了，返修第二天就收到录用通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f6e5643288, createdName=ms5000001106253574, createdTime=Mon Apr 18 20:10:06 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217201, encodeId=dd0e121e201a5, content=2.3开始外审，已经三个月了😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e55679937, createdName=ms5000001105610949, createdTime=Thu May 05 22:24:49 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235320, encodeId=da4b123532044, content=已经四个月了还在under review，是希望不大了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a0e8252933, createdName=ms3000001828306819, createdTime=Thu Jul 28 18:05:11 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232397, encodeId=3fc7123239e9f, content=为何发表在Arabian Journal of Chemistry上的文章WOS检索不到？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e001326649, createdName=kezhang0601, createdTime=Thu Jul 14 11:07:55 CST 2022, time=2022-07-14, status=1, ipAttribution=)]

2022-04-18 ms5000001106253574

审稿速度:2.0 | 投稿命中率:50.0
经验分享：返修要补部分实验，数据处理花了一定时间，给编辑发邮件说明原因后延长了一个月，但是期间还是花时间认真改了，返修第二天就收到录用通知

38 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2147288, encodeId=58a7214e28838, content=审稿速度:3.0 经验分享：研究型论文 Initial Date Submitted 3.16 Under Review 3.18 revise and resubmit your manuscrip 6.26 返稿 7.6 Received at Editorial Office 7.7 总体感觉还是比较nice的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/1cb160e8258640c2b57d7628095e3585/e81c07fcc6594229a97371ee25978df2.jpg, createdBy=66fe2398250, createdName=tsunamis, createdTime=Mon Jul 10 13:49:29 CST 2023, time=2023-07-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2089818, encodeId=5b3b208981827, content=2022.9.14 投稿，一周多了还是with editor正常吗，可以催稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=53f15071890, createdName=1459625am12暂无昵称, createdTime=Thu Sep 22 19:44:12 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181460, encodeId=2c492181460f1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：老天保佑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbfb9144040, createdName=ms4000000349532607, createdTime=Sat Jan 13 21:00:26 CST 2024, time=2024-01-13, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2174434, encodeId=5c1221e443401, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：药效物质基础;中药学 经验分享：2023年5月28日投稿，7月30日催稿后才进入了under review,一直到10月20日催稿，被告知一直未能成功邀请审稿人，继续催稿，又一个月左右邀请了7个审稿人，6个退修，剩余1个审稿人意见比较负面，2023年12月11日被退稿，说不能录用。太扯淡了，编辑及其不负责任，一直不重新邀请审稿人，投稿半年被拒了，简直是浪费时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13718827213, createdName=ms4000000272566761, createdTime=Tue Dec 12 10:43:34 CST 2023, time=2023-12-12, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2173223, encodeId=eeb321e3223a3, content=偏重的研究方向：药物分析 经验分享：10月31号提交的，一个多月了，还在with editor。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52d66486947, createdName=ms9000001055760114, createdTime=Wed Dec 06 11:44:52 CST 2023, time=2023-12-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2129005, encodeId=df4f2129005c5, content=审稿速度:2.0 经验分享：综述 Initial Date Submitted 7.25 Under Review8.27 revise and resubmit your manuscript9.14 返稿9.26 Received at Editorial Office25 Jul 2022Article revised26 Sep 2022Article accepted for publication9 Oct 2022 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddc56394096, createdName=ms7000000595986600, createdTime=Fri Apr 28 15:10:01 CST 2023, time=2023-04-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1212273, encodeId=250d12122e361, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：返修要补部分实验，数据处理花了一定时间，给编辑发邮件说明原因后延长了一个月，但是期间还是花时间认真改了，返修第二天就收到录用通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f6e5643288, createdName=ms5000001106253574, createdTime=Mon Apr 18 20:10:06 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217201, encodeId=dd0e121e201a5, content=2.3开始外审，已经三个月了😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e55679937, createdName=ms5000001105610949, createdTime=Thu May 05 22:24:49 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235320, encodeId=da4b123532044, content=已经四个月了还在under review，是希望不大了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a0e8252933, createdName=ms3000001828306819, createdTime=Thu Jul 28 18:05:11 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232397, encodeId=3fc7123239e9f, content=为何发表在Arabian Journal of Chemistry上的文章WOS检索不到？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e001326649, createdName=kezhang0601, createdTime=Thu Jul 14 11:07:55 CST 2022, time=2022-07-14, status=1, ipAttribution=)]

2022-05-05 ms5000001105610949

2.3开始外审，已经三个月了😭

33 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2147288, encodeId=58a7214e28838, content=审稿速度:3.0 经验分享：研究型论文 Initial Date Submitted 3.16 Under Review 3.18 revise and resubmit your manuscrip 6.26 返稿 7.6 Received at Editorial Office 7.7 总体感觉还是比较nice的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/1cb160e8258640c2b57d7628095e3585/e81c07fcc6594229a97371ee25978df2.jpg, createdBy=66fe2398250, createdName=tsunamis, createdTime=Mon Jul 10 13:49:29 CST 2023, time=2023-07-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2089818, encodeId=5b3b208981827, content=2022.9.14 投稿，一周多了还是with editor正常吗，可以催稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=53f15071890, createdName=1459625am12暂无昵称, createdTime=Thu Sep 22 19:44:12 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181460, encodeId=2c492181460f1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：老天保佑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbfb9144040, createdName=ms4000000349532607, createdTime=Sat Jan 13 21:00:26 CST 2024, time=2024-01-13, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2174434, encodeId=5c1221e443401, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：药效物质基础;中药学 经验分享：2023年5月28日投稿，7月30日催稿后才进入了under review,一直到10月20日催稿，被告知一直未能成功邀请审稿人，继续催稿，又一个月左右邀请了7个审稿人，6个退修，剩余1个审稿人意见比较负面，2023年12月11日被退稿，说不能录用。太扯淡了，编辑及其不负责任，一直不重新邀请审稿人，投稿半年被拒了，简直是浪费时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13718827213, createdName=ms4000000272566761, createdTime=Tue Dec 12 10:43:34 CST 2023, time=2023-12-12, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2173223, encodeId=eeb321e3223a3, content=偏重的研究方向：药物分析 经验分享：10月31号提交的，一个多月了，还在with editor。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52d66486947, createdName=ms9000001055760114, createdTime=Wed Dec 06 11:44:52 CST 2023, time=2023-12-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2129005, encodeId=df4f2129005c5, content=审稿速度:2.0 经验分享：综述 Initial Date Submitted 7.25 Under Review8.27 revise and resubmit your manuscript9.14 返稿9.26 Received at Editorial Office25 Jul 2022Article revised26 Sep 2022Article accepted for publication9 Oct 2022 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddc56394096, createdName=ms7000000595986600, createdTime=Fri Apr 28 15:10:01 CST 2023, time=2023-04-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1212273, encodeId=250d12122e361, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：返修要补部分实验，数据处理花了一定时间，给编辑发邮件说明原因后延长了一个月，但是期间还是花时间认真改了，返修第二天就收到录用通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f6e5643288, createdName=ms5000001106253574, createdTime=Mon Apr 18 20:10:06 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217201, encodeId=dd0e121e201a5, content=2.3开始外审，已经三个月了😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e55679937, createdName=ms5000001105610949, createdTime=Thu May 05 22:24:49 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235320, encodeId=da4b123532044, content=已经四个月了还在under review，是希望不大了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a0e8252933, createdName=ms3000001828306819, createdTime=Thu Jul 28 18:05:11 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232397, encodeId=3fc7123239e9f, content=为何发表在Arabian Journal of Chemistry上的文章WOS检索不到？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e001326649, createdName=kezhang0601, createdTime=Thu Jul 14 11:07:55 CST 2022, time=2022-07-14, status=1, ipAttribution=)]

2022-07-28 ms3000001828306819

已经四个月了还在under review，是希望不大了吗

31 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2147288, encodeId=58a7214e28838, content=审稿速度:3.0 经验分享：研究型论文 Initial Date Submitted 3.16 Under Review 3.18 revise and resubmit your manuscrip 6.26 返稿 7.6 Received at Editorial Office 7.7 总体感觉还是比较nice的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/1cb160e8258640c2b57d7628095e3585/e81c07fcc6594229a97371ee25978df2.jpg, createdBy=66fe2398250, createdName=tsunamis, createdTime=Mon Jul 10 13:49:29 CST 2023, time=2023-07-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2089818, encodeId=5b3b208981827, content=2022.9.14 投稿，一周多了还是with editor正常吗，可以催稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=53f15071890, createdName=1459625am12暂无昵称, createdTime=Thu Sep 22 19:44:12 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181460, encodeId=2c492181460f1, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：老天保佑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbfb9144040, createdName=ms4000000349532607, createdTime=Sat Jan 13 21:00:26 CST 2024, time=2024-01-13, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2174434, encodeId=5c1221e443401, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：药效物质基础;中药学 经验分享：2023年5月28日投稿，7月30日催稿后才进入了under review,一直到10月20日催稿，被告知一直未能成功邀请审稿人，继续催稿，又一个月左右邀请了7个审稿人，6个退修，剩余1个审稿人意见比较负面，2023年12月11日被退稿，说不能录用。太扯淡了，编辑及其不负责任，一直不重新邀请审稿人，投稿半年被拒了，简直是浪费时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13718827213, createdName=ms4000000272566761, createdTime=Tue Dec 12 10:43:34 CST 2023, time=2023-12-12, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2173223, encodeId=eeb321e3223a3, content=偏重的研究方向：药物分析 经验分享：10月31号提交的，一个多月了，还在with editor。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52d66486947, createdName=ms9000001055760114, createdTime=Wed Dec 06 11:44:52 CST 2023, time=2023-12-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2129005, encodeId=df4f2129005c5, content=审稿速度:2.0 经验分享：综述 Initial Date Submitted 7.25 Under Review8.27 revise and resubmit your manuscript9.14 返稿9.26 Received at Editorial Office25 Jul 2022Article revised26 Sep 2022Article accepted for publication9 Oct 2022 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddc56394096, createdName=ms7000000595986600, createdTime=Fri Apr 28 15:10:01 CST 2023, time=2023-04-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1212273, encodeId=250d12122e361, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：返修要补部分实验，数据处理花了一定时间，给编辑发邮件说明原因后延长了一个月，但是期间还是花时间认真改了，返修第二天就收到录用通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f6e5643288, createdName=ms5000001106253574, createdTime=Mon Apr 18 20:10:06 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217201, encodeId=dd0e121e201a5, content=2.3开始外审，已经三个月了😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e55679937, createdName=ms5000001105610949, createdTime=Thu May 05 22:24:49 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235320, encodeId=da4b123532044, content=已经四个月了还在under review，是希望不大了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a0e8252933, createdName=ms3000001828306819, createdTime=Thu Jul 28 18:05:11 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232397, encodeId=3fc7123239e9f, content=为何发表在Arabian Journal of Chemistry上的文章WOS检索不到？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e001326649, createdName=kezhang0601, createdTime=Thu Jul 14 11:07:55 CST 2022, time=2022-07-14, status=1, ipAttribution=)]

2022-07-14 kezhang0601

为何发表在Arabian Journal of Chemistry上的文章WOS检索不到？

38 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务